SUPN : Summary for Supernus Pharmaceuticals, Inc. - Yahoo Finance

U.S. Markets closed

Supernus Pharmaceuticals, Inc. (SUPN)


NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
24.70+1.25 (+5.33%)
At close: 4:00PM EST

24.70 -0.00 (-0.02%)
After hours: 4:46PM EST

People also watch
SCMPPCRXOMERRPTPHZNP
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close23.45
Open23.45
Bid0.00 x
Ask27.25 x 100
Day's Range23.40 - 25.30
52 Week Range9.51 - 27.50
Volume599,979
Avg. Volume541,900
Market Cap1.22B
Beta1.85
PE Ratio (TTM)50.41
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Supernus Pharmaceuticals, Inc. – Value Analysis (NASDAQ:SUPN) : January 23, 2017
    Capital Cube9 hours ago

    Supernus Pharmaceuticals, Inc. – Value Analysis (NASDAQ:SUPN) : January 23, 2017

    Categories: Fundamental Analysis Yahoo Finance Click here to see latest analysis Capitalcube gives Supernus Pharmaceuticals, Inc. a score of 75. Our analysis is based on comparing Supernus Pharmaceuticals, Inc. with the following peers – United Therapeutics Corporation, Zogenix, Inc., Alcobra Ltd., Bristol-Myers Squibb Company, Eli Lilly and Company, Shire PLC Sponsored ADR, Johnson & Johnson and Abbott Laboratories (UTHR-US, ZGNX-US, ... Read more (Read more...)

  • GlobeNewswire10 hours ago

    Supernus Files Form 10-Q for Third Quarter 2016 and Is Now Current with All Financial Filings

    ROCKVILLE, Md., Jan. 23, 2017-- Supernus Pharmaceuticals, Inc., a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, ...

  • Associated Press3 days ago

    Supernus misses 3Q revenue forecasts

    The Rockville, Maryland-based company said it had net income of $1.18 per share. Earnings, adjusted for pretax gains, came to 36 cents per share. The drugmaker posted revenue of $56.8 million in the period, ...